Repligen Clears HSR Antitrust Review for $1.5B BioLife Acquisition
RGEN sits 67% above its 52-week low of $100.99.
Summary
Repligen's $1.5B acquisition of BioLife Solutions cleared HSR antitrust review on September 3, 2026. The deal now awaits BioLife stockholder approval on October 5, 2026.
Key Events · M&A and Partnerships · RGEN
-
HSR Waiting Period Expired
The Hart-Scott-Rodino antitrust waiting period for the BioLife Solutions acquisition expired at 11:59 p.m. ET on September 3, 2026, clearing a key regulatory condition.
-
Deal Terms Unchanged
BioLife stockholders will receive $11.25 cash plus 0.1442 shares of Repligen common stock per BioLife share, valuing the deal at approximately $1.5 billion.
-
Next Milestone: Stockholder Vote
BioLife's special stockholder meeting to approve the merger is scheduled for October 5, 2026 at 9:00 a.m. ET via remote communication.
-
Remaining Conditions
Completion remains subject to customary closing conditions, including BioLife stockholder adoption of the merger agreement.
Analysis · RGEN · Life Sciences
The Hart-Scott-Rodino waiting period expired on September 3, 2026, removing a major regulatory hurdle for Repligen's $1.5 billion acquisition of BioLife Solutions. This was the last significant antitrust clearance needed before the deal can close. The merger still requires BioLife stockholder approval at the October 5, 2026 special meeting, but HSR clearance materially de-risks the transaction and moves it closer to completion.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.1% of the 2014 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RGEN was trading at $168.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.5B. The 52-week trading range was $100.99 to $188.73. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.